To explore the role of endogenous GABA in NMDA antagonist induced dopamine (DA) release, we used in vivo microdialysis to study the effects of pretreatment with ␥ -vinyl GABA (GVG) on phencyclidine (PCP)-inducedN-methyl-D-aspartate (NMDA) glutamate-receptor antagonists like phencyclidine (PCP) and ketamine, traditionally considered substances of abuse, have more recently assumed a compelling role in exploratory paradigms of schizophrenic psychoses (Javitt and Zukin 1991). In the past, conventional experimental models of schizophrenia focused on the effects of d-amphetamine, primarily because these and other psychostimulants directly increased dopamine (DA) release and induced a paranoid psychotic state in healthy controls similar to schizophrenia (Angrist and Gershon 1970;Wolkin et al. 1994). However, more recent models of schizophrenia focus on the effects of PCP and other NMDA antagonists, which produce psychoses that also incorporate the negative symptoms associated with schizophrenic illness (Javitt and Zukin 1991;Krystal et al. 1994). The psychotomimetic properties of NMDA antagonists provide a clinical foundation from which we can design novel treatment strategies targeted at diminishing aberrant neurochemical behavior. Investigations of the neurochemical interactions associated with NMDA antagonist-induced pathologies share the common denominator of increased subcortical DA concentrations and from this, many investigations have attempted to elucidate the events that produce abnormal DA activity. NMDA antagonists block excitatory amino acid (EAA) transmission at the NMDA receptor complex (Yamamoto et al. 1999). From this, many explanations suggest a hypo-glutamatergic state where diminished glutamatergic activity fails to activate the large number of inhibitory gamma aminobutyric acid (GABA) interneurons in the prefrontal cortex (PFC) (Yonezawa et al. 1998) or ventral tegmental area (VTA) (Bonci and Malenka 1999). This may produce dysfunctional cortical regulation of subcortical DA systems (Farber et al. 1998;Grace 1991). Indeed, local application of GABA receptor agonists dramatically reduces PCP-induced increases in PFC Yonezawa et al. 1998) and NAcc DA Wu et al. 1999).On the other hand, a solid body of evidence indicates that a hyperactive glutamatergic state mediates increases in DA activity secondary to NMDA antagonist administration. Microdialysis studies have demonstrated concurrent increases in glutamatergic and dopaminergic activity in the PFC, Nacc, and VTA in response to an NMDA antagonist challenge (Moghaddam et al. 1997;Karreman et al. 1996;Svensson et al. 1997;Takahata and Moghaddam 1998). Unanticipated increases in glutamatergic activity in response to NMDA antagonism were attributed to increased synaptic availability of glutamate at non-NMDA alpha-amino-3-hydroxy-5-metyloisoxazolo-4-propionate (AMPA)/kainate glutamate receptors.Consistent with this hypothesis, systemic and local pretreatment with AMPA/kainate glutamate receptor antagonists reduced or completely blocked dopaminergic responsi...